Addendum
Mirikizumab (Crohn's disease) - Addendum to Project A25-42
Report documents
-
Addendum
Mirikizumab (Crohn's disease) - Addendum to Project A25-42
Dossier assessment
Indication:
Adults with moderately to severely active Crohn’s disease
Result of dossier assessment:
- Patients who have had an inadequate response with, lost response to, or were intolerant to conventional therapy: unchanged after addendum: added benefit not proven
- Patients who have had an inadequate response with, lost response to, or were intolerant to a biologic agent (TNFα antagonist or integrin inhibitor or interleukin inhibitor): unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2025-09-04 A G-BA decision was published.
Project details
- Project no.
- A25-99
- Commission
- Commission awarded on 29.07.2025 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A25-99_en
Connected Projects
-
Dossier assessment
Mirikizumab (Crohn’s disease) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed